帮写一篇高中英语作文

In 2004, the EU's " traditional botanical drug registration procedures " (hereinafter referred to as " instruction instruction " ) requires that all plants for medicine production enterprises must be in by 30 April 2011 to complete the registration, otherwise not allowed in the EU territory sales and use.
From China Chamber of Commerce for import & export data shows, 2011 1-2 month our country Chinese traditional medicine products exports to the EU's amount is 4845961 kilograms, exit forehead is 60392000 dollar. Based on this data estimation, annual our country Chinese medicine products exports to the EU's total lack of EU 4% market share. The market for Chinese enterprises not only big, and unlimited potential.
But sadly, Chinese enterprises have not yet had time to develop this market was shut sb. Out.
In the face of tens of billions of the temptation of the market, seven years of preparation time, what hinders China Chinese enterprises enter the European Union?
The consultant in the pharmaceutical industry researcher Guo Fanli thought, Chinese enterprises generally small in scale, low profits, export capacity is weak, do not pay attention to the EU market. " China's small Chinese medicine enterprises accounted for more than 80%, with the local sales, out of the province is not much, not to mention abroad. " Moreover, Chinese medicine export mainly to Asian markets, especially in Japan and South Korea, China to do medicine roughing, finishing and sales of import countries. " Chinese pharmaceutical enterprises in the industrial chain of the bottom end, which is the most primary stage. " Therefore, the development of the EU market for Chinese enterprises is a little distant.
There are also many enterprises think, the EU access requirements are too strict, which adopted a wait-and-see attitude, we hope that the EU will relax regulation. " The enterprise thinks, other companies do, only do certification, if the EU to relax the standards, their great effort was not worth the investment. " Liu Zhanglin said. Therefore, Chinese enterprises to the EU market enthusiasm and look like the outside expected upsurge.
2004年，欧盟出台的《传统植物药注册程序指令》(下称《指令》)规定所有植物药生产企业必须在2011年4月30日前完成注册，否则不允许在欧盟境内销售和使用。
来自中国医药保健品进出口商会的数据显示，2011年1-2月我国中药类产品出口欧盟的数量为4845961公斤，出口额为6039.2万美元。基于此数据估算，每年我国中药类产品出口欧盟的总额不足欧盟市场份额的4%。这个市场对于中国中药企业来说不仅庞大，而且潜力无限。
但令人沮丧的是，中国中药企业还没有来得及开发这个市场就被拒之门外了。
面对百亿市场的诱惑，七年的准备时间，是什么阻碍了中国中药企业进入欧盟呢？
中投顾问医药行业研究员郭凡礼认为，中国中药企业普遍规模小、利润薄、出口能力弱，对欧盟市场并不重视。“我国小型中药企业占到80%以上，以本地销售为主，出省的都不多，更何况出国。”而且，中国中成药出口以亚洲市场为主，尤其是日本和韩国，中国做药材粗加工，进口国家做精加工和销售。“中国药企处于产业链的最底端，也是最初级的阶段。”因此，开发欧盟市场对于中国中药企业来说略显遥远。
也有不少企业认为，欧盟的准入要求过于严苛，从而持观望态度，希望欧盟会放松监管。“这些企业认为，别的公司不做，只有自己做了认证，如果欧盟放宽标准，自己投入很大精力并不值得。”刘张林介绍说。因此，中国中药企业对欧盟市场的热情并不像外界期望的那样高涨。

Background: the European Union to make regulation: one thousand kinds of Chinese traditional medicine unless given drug license, or to not allow the eu market sales. Theme: ban traditional Chinese medicine whether reasonable results: 79% is not reasonable, compared with traditional Chinese medicine and western medicine people use with one thousand years history, Chinese traditional medicine of natural, safe and effective. 21% is reasonable, the traditional Chinese medicine may have side effects, in the security not get the g cases should not be sales

Background: the European Union to make regulation: one thousand kinds of Chinese traditional medicine unless given drug license, or to not allow the eu market sales. Theme: ban traditional Chinese medicine whether reasonable results: 79% is not reasonable, compared with traditional Chinese medicine and western medicine people use with one thousand years history, Chinese traditional medicine of natural, safe and effective. 21% is reasonable, the traditional Chinese medicine may have side effects,呵呵，